OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Figlin on Toxicity Profile of Immunotherapy/VEGF TKI Combinations in RCC

May 9th 2019

Robert A. Figlin, MD, Steven Spielberg Family Chair in Hematology Oncology, director, Division of Hematology/Oncology, deputy director, Integrated Oncology Service Line, and professor of Biomedical Sciences, Medicine, at Cedars-Sinai Medical Center, discusses the toxicity profiles of combinations of immune checkpoint inhibitors and VEGF TKIs in renal cell carcinoma (RCC), as well as research being done to validate potential biomarkers in the space.

Dr. Duncan on the Expansion of CAR T-Cell Therapy

May 9th 2019

Christine N. Duncan, MD, a senior physician at Dana-Farber Cancer Institute, and assistant professor of pediatrics, Harvard Medical School, discusses the expansion of CAR T-cell therapy in oncology.

Dr. Shields Discusses the Prevalence of Genetic Testing in CRC

May 9th 2019

Anthony Shields, MD, PhD, professor, Department of Oncology, Molecular Imaging and Diagnostics Program, Karmanos Cancer Institute, discusses the prevalence of genetic testing colorectal cancer.

Dr. Philip on FOLFIRINOX in Locally Advanced Pancreatic Cancer

May 9th 2019

Philip A. Philip, MD, PhD, FRCP, professor, Department of Oncology, Karmanos Cancer Institute, discusses the use of FOLFIRINOX in patients with locally advanced pancreatic cancer.

Dr. Sznol on Patient Selection for Combination Therapy in mRCC

May 9th 2019

Mario Sznol, MD, professor of medicine, co-director, Yale SPORE in Skin Cancer, Yale Cancer Center, discusses patient selection for combination therapy in metastatic renal cell carcinoma.

Dr. Hari Discusses the Role of MRD in Myeloma

May 8th 2019

Parameswaran Hari, MD, MRCP, the Armand J. Quick/William F. Stapp Professor of Hematology, and the chief of the Division of Hematology/Oncology, Department of Medicine, at the Medical College of Wisconsin, discusses the role of minimal residual disease in myeloma.

Dr. Jonasch on Molecular Understanding of Clear Cell RCC

May 8th 2019

Eric Jonasch, MD, professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the molecular understanding of clear cell renal cell carcinoma (RCC).

Dr. Zhu on Primary Resistance to Osimertinib in EGFR-Mutant NSCLC

May 8th 2019

You-cai Zhu, MD, PhD, Department of Thoracic Disease Diagnosis and Treatment Center, Zhejiang Rongjun Hospital, discusses primary resistance to osimertinib (Tagrisso) in EGFR-mutant non–small cell lung cancer (NSCLC).

Dr. Bauml on Locally Ablative Therapy in Oligometastatic NSCLC

May 8th 2019

Joshua Bauml, MD, assistant professor, Perelman School of Medicine, University of Pennsylvania, discusses the use of locally ablative therapy in patients with oligometastatic non–small cell lung cancer.

Dr. Liu on the Potential of Pembrolizumab in SCLC

May 8th 2019

Stephen Liu, MD, associate professor of medicine, Division of Hematology and Oncology, Georgetown University Medical Center, discusses the potential of pembrolizumab in the treatment of patients with small cell lung cancer.

Dr. Brander on the Safety and Efficacy of Ibrutinib/Venetoclax in CLL

May 7th 2019

Danielle M. Brander, MD, assistant professor of medicine, Duke Cancer Institute, discusses the safety and efficacy of the combination of venetoclax (Venclexta) and ibrutinib (Imbruvica) in patients with chronic lymphocytic leukemia (CLL).

Dr. Galal on Ways of Extending the Reach of CAR T-Cell Therapy

May 7th 2019

Ahmed Galal, MD, instructor, Department of Medicine, Duke Cancer Institute, discusses ways of extending the reach of CAR T-cell therapy in real-world practice.

Dr. Fenske on the Future of Daratumumab in MCL

May 7th 2019

Timothy Fenske, MD, MS, associate professor, Medical College of Wisconsin, discusses the future of daratumumab (Darzalex) in mantle cell lymphoma (MCL).

Dr. Leitao Discusses the Role of HIPEC in Advanced Ovarian Cancer

May 7th 2019

Mario M. Leitao Jr, MD, FACOG, FACS, fellowship director, gynecology service, director, Minimal Access and Robotic Surgery Program, Department of Surgery, Memorial Sloan Kettering Cancer Center, discusses the role of HIPEC in patients with advanced ovarian cancer.

Dr. Kelly Discusses the Treatment of Patients With ALK+ NSCLC

May 7th 2019

Ronan J. Kelly, MD, MBA, chief of oncology for the ten Baylor Scott and White Health's North Texas Cancer Centers and director of oncology on the campus of Baylor Charles A. Sammons Cancer Center at Baylor University Medical Center, discusses the treatment of patients with ALK-positive non–small cell lung cancer.

Dr. Higano on the Toxicity of Androgen Receptor Inhibitors in CRPC

May 7th 2019

Celestia Higano, MD, FACP, member, Clinical Research Division, Fred Hutchinson Cancer Research Center, professor, Department of Medicine and Urology, University of Washington, Seattle Cancer Care Alliance, discusses the toxicity of androgen receptor inhibitors in castration-resistant prostate cancer.

Dr. McGregor on Implications of the FDA Approval of Pembrolizumab/Axitinib in RCC

May 4th 2019

Bradley McGregor, MD, clinical director, Lank Center for Genitourinary Oncology, senior physician, Dana-Farber Cancer Institute, and instructor of medicine, Harvard Medical School, discusses the clinical implications of the FDA approval of pembrolizumab (Keytruda) and axitinib (Inlyta) in advanced renal cell carcinoma (RCC).

Dr. Grivas on Investigational Immunotherapy Approaches in Localized Bladder Cancer

May 4th 2019

Petros Grivas, MD, PhD, clinical director of the Genitourinary Cancers Program and associate professor, Department of Medicine, Division of Oncology, University of Washington, and medical oncologist, Seattle Cancer Care Alliance, discusses investigational immunotherapy approaches in localized bladder cancer.

Dr. Einstein on Biochemical Recurrence in Prostate Cancer

May 4th 2019

David J. Einstein, MD, instructor of medicine at Harvard Medical School, and attending physician of medicine at Beth Israel Deaconess Medical Center, discusses biochemical recurrence in patients with prostate cancer.

Dr. Stahel on Treatment Sequencing in Stage IV NSCLC

May 3rd 2019

Rolf A. Stahel, MD, professor in the oncology clinic, University Hospital, Zurich, discusses treatment sequencing in stage IV non–small cell lung cancer.